Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Investment Securities (2019 - 2025)

Cyclerion Therapeutics has reported Gains from Investment Securities over the past 6 years, most recently at $315394.0 for Q3 2025.

  • Quarterly results put Gains from Investment Securities at $315394.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $315394.0 (changed N/A YoY), and the annual figure for FY2024 was $335448.0, up 67.72%.
  • Gains from Investment Securities for Q3 2025 was $315394.0 at Cyclerion Therapeutics, down from $329458.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CYCN hit a ceiling of $540000.0 in Q4 2022 and a floor of -$6.0 million in Q4 2021.
  • Median Gains from Investment Securities over the past 4 years was $329458.0 (2025), compared with a mean of -$281740.7.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 3048.81% in 2021 and later skyrocketed 594.51% in 2022.
  • Cyclerion Therapeutics' Gains from Investment Securities stood at -$6.0 million in 2021, then skyrocketed by 108.93% to $540000.0 in 2022, then crashed by 87.96% to $65000.0 in 2024, then surged by 385.22% to $315394.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $315394.0 (Q3 2025), $329458.0 (Q1 2025), and $65000.0 (Q2 2024) per Business Quant data.